Gene Therapy Safety In Cardiovascular Disease Defended at ACC
This article was originally published in The Gray Sheet
Executive Summary
FDA's decision to place four gene therapy trials sponsored by Vascular Genetics on hold the week of Feb. 28 did not result from the non-reporting of patient deaths, according to lead investigator Jeff Isner, MD, St. Elizabeth's Medical Center, Boston.